[ CAS No. 2140-79-6 ] {[proInfo.proName]}

Name: 2140-79-6|(2R,3R,4R,5R)-5-(6-Amino-9H-purin-9-yl)-2-(hydroxymethyl)-4-methoxytetrahydrofuran-3-ol|98%
Brand: Ambeed
SKU: A362743
Price: 11.0 USD
Availability: InStock
Rating: 99 (27 reviews)

,{[proInfo.pro_purity]}

Cat. No.: {[proInfo.prAm]}

DV 2D 3D

3d Animation Molecule Structure of 2140-79-6

Structure of 2140-79-6 * Storage: {[proInfo.prStorage]}

Cart0 Add to My Favorites Add to My Favorites Bulk Inquiry Inquiry Add To Cart

Search after Editing

* Storage: {[proInfo.prStorage]}

For Research Only 110K+ Compounds Competitive Price 1-2 Day Shipping

Quality Control of [ 2140-79-6 ]

COA NMR CNMR HPLC LC-MS

Related Doc. of [ 2140-79-6 ]

SDS Specification

Alternatived Products of [ 2140-79-6 ]

Product Details of [ 2140-79-6 ]

CAS No. :	2140-79-6	MDL No. :
Formula :	C₁₁H₁₅N₅O₄	Boiling Point :	-
Linear Structure Formula :	-	InChI Key :	FPUGCISOLXNPPC-IOSLPCCCSA-N
M.W :	281.27	Pubchem ID :	102213
Synonyms :		Chemical Name :	(2R,3R,4R,5R)-5-(6-Amino-9H-purin-9-yl)-2-(hydroxymethyl)-4-methoxytetrahydrofuran-3-ol

Calculated chemistry of [ 2140-79-6 ]

Physicochemical Properties

Num. heavy atoms :	20
Num. arom. heavy atoms :	9
Fraction Csp3 :	0.55
Num. rotatable bonds :	3
Num. H-bond acceptors :	7.0
Num. H-bond donors :	3.0
Molar Refractivity :	67.4
TPSA :	128.54 Å²

Pharmacokinetics

GI absorption :	Low
BBB permeant :	No
P-gp substrate :	No
CYP1A2 inhibitor :	No
CYP2C19 inhibitor :	No
CYP2C9 inhibitor :	No
CYP2D6 inhibitor :	No
CYP3A4 inhibitor :	No
Log Kp (skin permeation) :	-8.38 cm/s

Lipophilicity

Log Po/w (iLOGP) :	1.24
Log Po/w (XLOGP3) :	-0.51
Log Po/w (WLOGP) :	-1.64
Log Po/w (MLOGP) :	-2.02
Log Po/w (SILICOS-IT) :	-1.89
Consensus Log Po/w :	-0.96

Druglikeness

Lipinski :	0.0
Ghose :	None
Veber :	0.0
Egan :	0.0
Muegge :	0.0
Bioavailability Score :	0.55

Water Solubility

Log S (ESOL) :	-1.4
Solubility :	11.3 mg/ml ; 0.04 mol/l
Class :	Very soluble
Log S (Ali) :	-1.72
Solubility :	5.34 mg/ml ; 0.019 mol/l
Class :	Very soluble
Log S (SILICOS-IT) :	-0.29
Solubility :	145.0 mg/ml ; 0.514 mol/l
Class :	Soluble

Medicinal Chemistry

PAINS :	0.0 alert
Brenk :	0.0 alert
Leadlikeness :	0.0
Synthetic accessibility :	4.01

Safety of [ 2140-79-6 ]

Signal Word:	Warning	Class:	N/A
Precautionary Statements:	P280-P305+P351+P338	UN#:	N/A
Hazard Statements:	H302	Packing Group:	N/A
GHS Pictogram:

Application In Synthesis of [ 2140-79-6 ]

* All experimental methods are cited from the reference, please refer to the original source for details. We do not guarantee the accuracy of the content in the reference.

Downstream synthetic route of [ 2140-79-6 ]

[ 2140-79-6 ] Synthesis Path-Downstream 1~88

1
[ 2140-79-6 ]
[ 24121-00-4 ]

Reference： [1]Organic Letters,2004,vol. 6,p. 233 - 236
[2]Biochemistry,1972,vol. 11,p. 4931,4932
[3]Journal of Medicinal Chemistry,2009,vol. 52,p. 5485 - 5495

2
[ 186581-53-3 ]
[ 58-61-7 ]
[ 2140-79-6 ]

Reference： [1]Cellular and Molecular Life Sciences,1998,vol. 54,p. 125 - 128
[2]Synthetic Procedures in Nucleic Acid Chemistry,Bd. 1<New York 1968>S.207,

3
[ 28920-43-6 ]
[ 2140-79-6 ]
[ 135944-25-1 ]
2'-O-methyl-6-bis-N-(9-fluorenylmethoxycarbonyl)adenosine [ No CAS ]

Reference： [1]Journal of Organic Chemistry,1991,vol. 56,p. 5846 - 5859
[2]Journal of Organic Chemistry,1991,vol. 56,p. 5846 - 5859

4
[ 2181-42-2 ]
[ 2140-79-6 ]
[ 91101-00-7 ]

Reference： [1]Journal of the Chemical Society. Perkin transactions I,1980,p. 2787 - 2792
[2]Journal of the Chemical Society. Perkin transactions I,1980,p. 2787 - 2792

5
[ 17287-03-5 ]
[ 2140-79-6 ]
[ 57817-83-1 ]
[ 20649-46-1 ]
[ 91101-00-7 ]
[ 30891-53-3 ]

Reference： [1]Journal of the Chemical Society. Perkin transactions I,1980,p. 2787 - 2792
[2]Journal of the Chemical Society. Perkin transactions I,1980,p. 2787 - 2792

6
[ 2140-79-6 ]
[ 92611-10-4 ]
2'-O-methyl-cis-adenosine 3',5'-cyclic methyl monophosphite [ No CAS ]

Reference： [1]Canadian Journal of Chemistry,1993,vol. 71,p. 855 - 863

7
[ 2140-79-6 ]
[ 74230-06-1 ]
[ 57817-83-1 ]
[ 20649-46-1 ]

Reference： [1]Journal of the Chemical Society. Perkin transactions I,1985,p. 1327 - 1330
[2]Journal of the Chemical Society. Perkin transactions I,1985,p. 1327 - 1330
[3]Journal of the Chemical Society. Perkin transactions I,1985,p. 1327 - 1330

8
[ 512-56-1 ]
[ 58-61-7 ]
[ 57817-83-1 ]
[ 2140-79-6 ]
[ 1867-73-8 ]
[ 10300-22-8 ]

Reference： [1]Bulletin of the Chemical Society of Japan,1981,vol. 54,p. 1569 - 1570

9
[ 512-56-1 ]
[ 58-61-7 ]
[ 60037-52-7 ]
[ 57817-83-1 ]
[ 2140-79-6 ]
[ 10300-22-8 ]

Reference： [1]Bulletin of the Chemical Society of Japan,1981,vol. 54,p. 1569 - 1570

10
[ 17287-03-5 ]
[ 58-61-7 ]
[ 60037-52-7 ]
[ 57817-83-1 ]
[ 2140-79-6 ]
[ 15763-06-1 ]

Reference： [1]Journal of the Chemical Society. Perkin transactions I,1980,p. 2787 - 2792

11
[ 17287-03-5 ]
[ 58-61-7 ]
[ 60037-52-7 ]
[ 2140-79-6 ]
[ 1867-73-8 ]
[ 2620-62-4 ]

Reference： [1]Journal of the Chemical Society. Perkin transactions I,1980,p. 2787 - 2792

12
[ 17287-03-5 ]
[ 58-61-7 ]
[ 60037-52-7 ]
[ 57817-83-1 ]
[ 2140-79-6 ]
[ 1867-73-8 ]
[ 10300-22-8 ]

Reference： [1]Bulletin of the Chemical Society of Japan,1986,vol. 59,p. 2947 - 2949

13
[ 17287-03-5 ]
[ 58-61-7 ]
[ 57817-83-1 ]
[ 2140-79-6 ]
[ 1867-73-8 ]
[ 10300-22-8 ]

Reference： [1]Bulletin of the Chemical Society of Japan,1986,vol. 59,p. 2947 - 2949
[2]Journal of Organic Chemistry,1980,vol. 45,p. 3865 - 3868
[3]Journal of the Chemical Society. Perkin transactions I,1980,p. 2787 - 2792

14
[ 17287-03-5 ]
[ 58-61-7 ]
[ 60037-52-7 ]
[ 57817-83-1 ]
[ 2140-79-6 ]
[ 10300-22-8 ]

Reference： [1]Journal of Organic Chemistry,1980,vol. 45,p. 3865 - 3868
[2]Journal of Organic Chemistry,1980,vol. 45,p. 3865 - 3868
[3]Journal of the Chemical Society. Perkin transactions I,1980,p. 2787 - 2792

15
[ 17287-03-5 ]
[ 58-61-7 ]
[ 57817-83-1 ]
[ 20649-46-1 ]
[ 2140-79-6 ]
[ 10300-22-8 ]

Reference： [1]Journal of Organic Chemistry,1980,vol. 45,p. 3865 - 3868

16
[ 1899-02-1 ]
[ 58-61-7 ]
[ 60037-52-7 ]
[ 2140-79-6 ]
[ 1867-73-8 ]
[ 10300-22-8 ]

Reference： [1]Synthetic Communications,1980,vol. 10,p. 25 - 36

17
[ 1899-02-1 ]
[ 58-61-7 ]
[ 57817-83-1 ]
[ 2140-79-6 ]
[ 1867-73-8 ]
[ 10300-22-8 ]

Reference： [1]Synthetic Communications,1980,vol. 10,p. 25 - 36

18
[ 74230-06-1 ]
[ 58-61-7 ]
[ 57817-83-1 ]
[ 2140-79-6 ]
[ 15763-06-1 ]
[ 1867-73-8 ]

Reference： [1]Journal of the Chemical Society. Perkin transactions I,1985,p. 1327 - 1330

19
[ 74230-06-1 ]
[ 58-61-7 ]
[ 60037-52-7 ]
[ 57817-83-1 ]
[ 2140-79-6 ]
[ 1867-73-8 ]

Reference： [1]Journal of the Chemical Society. Perkin transactions I,1985,p. 1327 - 1330

20
[ 74230-06-1 ]
[ 58-61-7 ]
[ 57817-83-1 ]
[ 20649-46-1 ]
[ 2140-79-6 ]
[ 1867-73-8 ]

Reference： [1]Journal of the Chemical Society. Perkin transactions I,1985,p. 1327 - 1330
[2]Journal of the Chemical Society. Perkin transactions I,1985,p. 1327 - 1330

21
[ 74230-06-1 ]
[ 58-61-7 ]
[ 60037-52-7 ]
[ 57817-83-1 ]
[ 2140-79-6 ]
[ 10300-22-8 ]

Reference： [1]Journal of the Chemical Society. Perkin transactions I,1985,p. 1327 - 1330
[2]Journal of the Chemical Society. Perkin transactions I,1985,p. 1327 - 1330

22
[ 58-61-7 ]
[ 74-88-4 ]
[ 2140-79-6 ]
[ 10300-22-8 ]

Reference： [1]Journal of Organic Chemistry,1991,vol. 56,p. 5846 - 5859

23
[ 2140-79-6 ]
[ 1608-26-0 ]
2'-O-methyl-trans-adenosine 3',5'-cyclic N,N-dimethylphosphoramidite [ No CAS ]

Reference： [1]Journal of the American Chemical Society,1992,vol. 114,p. 9624 - 9633

24
[ 75-77-4 ]
[ 2140-79-6 ]
O^{3'_,O5'}-bis-(tert-butyl-dimethyl-silanyl)-O^2'-methyl-adenosine [ No CAS ]

Reference： [1]Tetrahedron Letters,1995,vol. 36,p. 9277 - 9280
[2]Phosphorus, Sulfur and Silicon and the Related Elements,1999,vol. 144-146,p. 363 - 366

25
[ 524-38-9 ]
[ 2140-79-6 ]
[ 183737-02-2 ]

Reference： [1]Journal of Organic Chemistry,1996,vol. 61,p. 8186 - 8199
[2]Nucleosides and Nucleotides,1997,vol. 16,p. 1629 - 1632

26
[ 2140-79-6 ]
[ 88091-70-7 ]
[ 185761-07-3 ]

Reference： [1]Helvetica Chimica Acta,1996,vol. 79,p. 2114 - 2136

27
[ 58-61-7 ]
[ 18107-18-1 ]
[ 2140-79-6 ]
[ 10300-22-8 ]

Reference： [1]Bioorganic and Medicinal Chemistry Letters,1996,vol. 6,p. 2993 - 2998

28
[ 2140-79-6 ]
Phosphoric acid mono-[(2R,3R,4R,5R)-5-(6-amino-purin-9-yl)-4-methoxy-2-phosphonooxymethyl-tetrahydro-furan-3-yl] ester [ No CAS ]

Reference： [1]Journal of Medicinal Chemistry,1998,vol. 41,p. 183 - 190

29
[ 2140-79-6 ]
[ 3881-21-8 ]

Yield	Reaction Conditions	Operation in experiment
	With cis-nitrous acid; acetic acid; In water;	Commercially available 2?OMe-adenosine compound 14 was diazotized in aqueous acetic acid with nitrous acid to give compound 15 (step i) by the method of Hyde, 2003, J Med Chem, 46:1878-85 (hereby incorporated by reference). Compound 15 was converted to a compound 16 by the method of Miller, 2015, J Med Chem, 58:6248-6263 (hereby incorporated by reference) (step ii). The m62?OMe-adenosine product (compound 16) was protected by the method of Zhu, 2003, Synthetic Communications, 33:1233-43 (hereby incorporated by reference) (step iii). The adenosine compound was reacted with 1.1 equivalents of TMSCl per hydroxy group together with 1.2 equivalents of benzoyl chloride to produce TMS-modified, mono-benzoylated m62?OMe-adenosine. The TMSA groups were removed under aqueous acidic conditions in THF-TFA to give compound 17 (step iii). The 5?-hydroxy was reacted with DMT-Cl to form an ether and the phosphorylated adenosine compound 18 was produced as in Example 2 by reaction with 4-chlorophenyl dichlorophosphate as a 3?-O-phosphorylating agent (FIG. 7, step iv) to produce benzoyl-3?-p-m62?-OMeA (compound 18).

Reference： [1]Journal of Medicinal Chemistry,2003,vol. 46,p. 1878 - 1885
[2]Cellular and Molecular Life Sciences,1998,vol. 54,p. 125 - 128
[3]Patent: US2018/105551,2018,A1 .Location in patent: Paragraph 0124

30
[ 2140-79-6 ]
[ 18162-48-6 ]
[ 221537-14-0 ]

Reference： [1]Tetrahedron Letters,1999,vol. 40,p. 1873 - 1876
[2]Chemical Communications,1999,p. 45 - 46
[3]Helvetica Chimica Acta,2000,vol. 83,p. 2477 - 2503

31
[ 2140-79-6 ]
[ 66224-66-6 ]
Phosphoric acid mono-((2R,3R,4R,5R)-4-hydroxy-5-hydroxymethyl-3-methoxy-tetrahydro-furan-2-yl) ester [ No CAS ]

Reference： [1]Nucleosides and Nucleotides,1999,vol. 18,p. 745 - 757

32
[ 76-83-5 ]
[ 2140-79-6 ]
[ 28990-73-0 ]

Reference： [1]Journal of the American Chemical Society,1999,vol. 121,p. 10270 - 10280

33
[ 2140-79-6 ]
[ 18162-48-6 ]
[ 251296-61-4 ]

Yield	Reaction Conditions	Operation in experiment
83%	With 1H-imidazole; dmap; In N,N-dimethyl-formamide; at 20℃; for 28h;	DMAP (20 mg, 0.18 mmol) and imidazole (580 mg, 8.54 mmol) were added to a solution of <strong>[2140-79-6]2'-O-methyladenosine</strong> (1) (200 mg, 0.71 mmol) in DMF (5.5 mL), followed by the addition of TBSCl (640 mg, 0.43 mmol) and stirred at room temperature. After 28 h, the reaction mixture was quenched with water and extracted with AcOEt. The organic layer was dried over Na2SO4, and evaporated to give a colorless oil. The crude oil was purified by column chromatography (Kanto 60 N, Hexane/AcOEt = 1:1) to give a white foam (300 mg, 0.589 mmol, 83%). (IR (cm-1): 2929, 2857, 1672, 1599, 1472. 1H NMR (400 MHz, CDCl3) delta (ppm): 8.32 (1H, s), 8.25 (1H, s), 6.30 (2H, br), 6.13 (1H, d, J = 3.7 Hz), 4.50 (1H, dd, J = 4.6, 5.2 Hz), 4.12-4.11 (H, m), 4.01-3.98 (1H, m), 3.79-3.76 (1H, m), 3.47 (3H, s), 0.92 (9H, s), 0.91 (9H, s), 0.10 (6H, s), 0.09 (6H, s). ESI-MS (M+H)+: 510.29.) A solution of this white foam (300 mg, 0.59 mmol) in CH2Cl2 (5.7 mL) was cooled to 0 C in an ice bath. TMSCl (145 muL) was dropwise added to the reaction mixture, and then tert-butylnitrite (350 muL) was dropwise added at 0 C. After stirring for 7 h at 0 C, the reaction mixture was quenched with a saturated NaHCO3 solution, and extracted with CH2Cl2. The organic layer was dried over Na2SO4, and evaporated to give a colorless oil. The oil was purified by column chromatography (Kanto 60 N, Hexane/AcOEt = 5:1) to give 2 as a colorless oil (115 mg, 0.22, 37%) and recovery of the starting material (57 mg, 0.11 mmol, 19%). IR (cm-1): 2929, 2857, 1587, 1559, 1472, 1333, 1126. 1H NMR (400 MHz, CDCl3) delta (ppm): 8.73 (1H, s), 8.51 (1H, s), 6.20 (2H, d, J = 4.0 Hz), 4.50 (1H, t, J = 4.9 Hz), 4.15-4.11 (2H, m), 3.99 (1H, dd, J = 3.1, 11 Hz), 3.78 (1H, dd, J = 2.4, 11 Hz), 3.47 (3H, s), 0.92 (9H, s), 0.91 (9H, s), 0.10 (6H, s), 0.09 (6H, s). 13C NMR (125 MHz, CDCl3) delta (ppm): 152.0, 151.2, 151.1, 143.9, 132.3, 87.0, 85.5, 84.1, 69.7, 61.9, 58.5, 26.0, 25.7, 18.5, 18.1, -4.7, -4.8, -5.3, -5.4. HRESI-MS m/z: calcd for (M+H)+ C23H42N4O4Si2Cl, 529.2428; found, 529.2476..
	With pyridine; 1H-imidazole; at 20℃; for 15h;	To a solution of 7-1 (15.0 g, 53.3 mmol) in dry pyridine (150 mL) was added TBSC1 (20.0 g, 133.3 mmol) and Imidazole (10.8 g, 159.9 mmol). The mixture was stirred at r.t. for l5h. TLC showed 7-1 was consumed completely. The reaction mixture was concentrated in vacuo to give residue. The residue was quenched with DCM (500 mL). The DCM layer was washed with H2O (1 L*2) 2 times and brine. The DCM layer concentrated in vacuo to give crude 7-2 (27.2 g, 53.3 mmol) as a yellow oil. The crude 7-2 was used in next step directly. ESI-LCMS m/z 510.5 [M+H]+.

Reference： [1]Journal of Organic Chemistry,1999,vol. 64,p. 8183 - 8192
[2]Bioorganic and Medicinal Chemistry,2016,vol. 24,p. 1308 - 1313
[3]Patent: WO2020/97342,2020,A1 .Location in patent: Paragraph 0138; 0139-0140

Yield	Reaction Conditions	Operation in experiment
0.25 g (80%)		2'-O-Methyl Adenosine (8) Solution of compound 7 (0.45 g, 1.17 mmol) in saturated methanolic ammonia (20 mL) was autoclaved at 125 C. for 4 hours. The solvent was removed in vacuo and remaining residue was purified by flash chromatography on silica gel. Elution with methylene chloride--methanol (9:1) mixture provided 0.25 g (80%) of 2'-O-methyl adenosine 8 as white solid. The analytical sample was recrystallized from abs EtOH. m.p. The product was identical to authentic sample by HPLC, UV-, 1 H-NMR-spectroscopy.

36
yeast-ribonucleic acid [ No CAS ]
[ 2140-79-6 ]

Reference： [1]Biochimica et biophysica acta,1959,vol. 31,p. 573 - 575

37
[ 17287-03-5 ]
[ 58-61-7 ]
[ 60037-52-7 ]
[ 57817-83-1 ]
[ 20649-46-1 ]
[ 2140-79-6 ]
[ 1867-73-8 ]
[ 10300-22-8 ]

Yield	Reaction Conditions	Operation in experiment
	With copper acetylacetonate In N,N-dimethyl-formamide at 70℃; for 1h;

Reference： [1]Yamauchi, Kiyoshi; Nakagima, Toru; Kinoshita, Masayoshi [Journal of Organic Chemistry, 1980, vol. 45, # 19, p. 3865 - 3868]

38
[ 194034-61-2 ]
[ 2140-79-6 ]

Yield	Reaction Conditions	Operation in experiment
80%		Subsequent amination of (7) with methanolic ammonia at 125 C. for 4 hours yields 2'-O-Methyl-adenosine (8) in 80% yield.

Reference： [1]Tetrahedron,2000,vol. 56,p. 1047 - 1056
[2]Patent: US5962675,1999,A

39
[ 17287-03-5 ]
[ 58-61-7 ]
[ 2140-79-6 ]

Reference： [1]Tetrahedron,2000,vol. 56,p. 1047 - 1056

40
[ 2140-79-6 ]
[ 268748-00-1 ]

Reference： [1]Nucleosides, nucleotides and nucleic acids,2000,vol. 19,p. 69 - 86

41
[ 58-61-7 ]
[ 74-88-4 ]
[ 2140-79-6 ]

Reference： [1]Journal of Medicinal Chemistry,2003,vol. 46,p. 1878 - 1885
[2]Helvetica Chimica Acta,2000,vol. 83,p. 2477 - 2503

42
[ 2140-79-6 ]
[ 123-76-2 ]
[ 647834-88-6 ]

Reference： [1]Journal of Organic Chemistry,2002,vol. 67,p. 4513 - 4519

43
[ 2140-79-6 ]
[ 647834-80-8 ]
5'-O-levulinyl-2'-O-methyladenosine [ No CAS ]

Reference： [1]Tetrahedron Asymmetry,2003,vol. 14,p. 3533 - 3540
[2]Nucleosides, nucleotides and nucleic acids,2003,vol. 22,p. 1455 - 1457

44
[ 2140-79-6 ]
[ 647834-80-8 ]
3'-O-levulinyl-2'-O-methyladenosine [ No CAS ]
5'-O-levulinyl-2'-O-methyladenosine [ No CAS ]
[ 647834-88-6 ]

Reference： [1]Tetrahedron Asymmetry,2003,vol. 14,p. 3533 - 3540
[2]Tetrahedron Asymmetry,2003,vol. 14,p. 3533 - 3540

45
[ 2140-79-6 ]
[ 98-88-4 ]
[ 1000003-68-8 ]

Yield	Reaction Conditions	Operation in experiment
72%	With pyridine; at 80℃; for 4h;	Example 15; Preparation of (2R,3R,4R,5R)-5-(6-amino-2-methoxy-9H-purin-9-yl)-2-(hvdroxymethyl)-4-methoxytetrahvdrofuran-3-ol 14; Scheme 14; To a solution of 2'-methoxy adenosine (1Og, 35.6mmol) in pyridine (75mL) was added benzoyl chloride (22.7mL, 196mmol) and the resulting solution was refluxed at 8O0C for 4h. The solvents were removed in vacuo and the residue dissolved in EtOAc and washed with aq. NaHCO3, brine and water, and the organic phase dried over MgSO4. Crystallisation from ethanol afforded 25 as a white solid in 2 batches (13.7g and 4.3g, 72% overall).
72%		To a solution of 2'-methoxy adenosine (10 g, 35.6 mmol) in pyridine (75 mL) was added benzoyl chloride (22.7 mL, 196 mmol) and the resulting solution was refluxed at 80 C. for 4 h. The solvents were removed in vacuo and the residue dissolved in EtOAc and washed with aq. NaHCO3, brine and water, and the organic phase dried over MgSO4. Crystallisation from ethanol afforded 26 as a white solid in 2 batches (13.7 g and 4.3 g, 72% overall).

Reference： [1]Patent: WO2008/745,2008,A2 .Location in patent: Page/Page column 47
[2]Patent: US2008/9461,2008,A1 .Location in patent: Page/Page column 14

46
[ 2140-79-6 ]
C₁₁H₁₃N₅O₅ [ No CAS ]

Reference： [1]Bioorganic and Medicinal Chemistry,2007,vol. 15,p. 5440 - 5447

47
[ 2140-79-6 ]
[ 49617-83-6 ]
N⁶-(3-iodobenzyl)-2'-O-methyladenosine [ No CAS ]